Drug Trial Radar · NCT07885293
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jul 2029
Study completion Jun 2033
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open label, randomized phase III clinical study that evaluates the efficacy of oral HS-10382 versus investigator selected TKIs (imatinib, nilotinib, dasatinib, and flumatinib) in newly diagnosed Ph+CML-CP adult participants. The TKI drug chosen by the investigators is the FDA/NMPA approved CML-CP first-line treatment drug: imatinib or nilotinib or dasatinib or flumatinib.
Conditions
- Chronic Myeloid Leukemia
Interventions
HS-10382Drug
Comes in 40 mg tablets and taken orally
ImatinibDrug
Comes in 100 mg tablets and taken orally
DasatinibDrug
Comes in 20 mg, 50 mg and 70 mg tablets and taken orally
NilotinibDrug
Comes in 150 mg capsules and taken orally
FlumatinibDrug
Comes in 0.2 g tablets and taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Major Molecular Response (MMR) at Week 48Time frame: At Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.